Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03485547
Title Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

hematologic cancer

Therapies

Venetoclax

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.